



Epidemiologisches Bulletin

6. Februar 2004 / Nr. 6 – Anlage AKTUELLE DATEN UND INFORMATIONEN ZU INFEKTIONSKRANKHEITEN UND PUBLIC HEALTH

Mitteilung der Ständigen Impfkommission (STIKO) am Robert Koch-Institut:
Hinweise für Ärzte zum Aufklärungsbedarf bei Schutzimpfungen/Stand: Januar 2004 – Literaturverzeichnis –

Fachinformationen der in Deutschland zugelassenen Impfstoffe

- 1 Fachinformationen der in Deutschland zugelassenen Präparate. Fachinformationsverzeichnis Deutschland (einschließlich EU-Zulassungen). CD-Version, Ausgabe 2003/4. BPI Service GmbH Frankfurt/Main

Literatur zu speziellen Impfungen

Diphtherie (D)-, Diphtherie-Tetanus (DT)-, Diphtherie-Tetanus-Pertussis (azellulär) (DTaP)- Impfstoff; 4-, 5- und 6-valente Impfstoffe auf DTaP-Basis (DTaP-Hib, DTaP-Hib-IPV, DTaP-Hib-IPV-HB)

- 2 Stratton KR, Howe CJ, Johnston RB Jr, eds. Adverse events associated with childhood vaccines. National Academy of Sciences: Washington, DC, 1994, section diphtheria and tetanus toxoids, pp 67–117.
- 3 Recommendations of the Advisory Committee on Immunization Practices (ACIP). Update: Vaccine side effects, adverse reactions, contraindications, and precautions. Morbid Mortal 1996; 45: No RR-12, section side effects and adverse reactions following DTP vaccination, p 22.
- 4 Schmitt HJ, Beutel K, Schuind A, et al. Reactogenicity and immunogenicity of a booster dose of a combined diphtheria, tetanus, and tricomponent acellular pertussis vaccine at fourteen to twenty-eight months of age. J Pediatr 1997; 130: 616–23.
- 5 Quast U, Thilo W, Fescharek R. Impfreaktionen – Bewertung und Differentialdiagnose. 2. Auflage. Hippokrates, Stuttgart 1997. Kapitel Diphtherie, S. 39–43.
- 6 Mortimer Jr EA, Wharton M. Diphtheria toxoid. In: Plotkin SA, Orenstein WA (eds) Vaccines. 3rd edition. Saunders, Philadelphia 1999, p 140.
- 7 Edwards KM, Decker MD, Mortimer Jr EA. Pertussis vaccine. In: Plotkin SA, Orenstein WA (eds). Vaccines. 3rd edition. Saunders, Philadelphia 1999, p 293.
- 8 Wassilak SGF, Orenstein WA, Sutter RW. Tetanus toxoid. In: Plotkin SA, Orenstein WA (eds). Vaccine. 3rd edition. Saunders, Philadelphia 1999, p 441.
- 9 Decker MD, Edwards KM. Combination vaccines. In: Plotkin SA, Orenstein WA (eds). Vaccines. 3rd edition. Saunders, Philadelphia 1999, p 508–530.
- 10 Use of DTaP vaccine as a five-dose series. Supplemental recommendations of the Advisory Committee on Immunization Practices (ACIP). Morbid Mortal Wkly Rep 2000; 49: No. RR-13.
- 11 American Academy of Pediatrics. Diphtheria. In: Pickering LK, ed. 2000 Red Book: Report of the Committee on Infectious Diseases. 25th ed. Elk Grove Village, IL; American Academy of Pediatrics 2000, p 230.
- 12 American Academy of Pediatrics. Pertussis. In: Pickering LK, ed. 2000 Red Book: Report of the Committee on Infectious Diseases. 25th ed. Elk Grove

Anlage zur Ausgabe 6/2004

Mitteilung der
 Ständigen Impfkommission
 (STIKO) am RKI:

Hinweise für Ärzte
 zum Aufklärungsbedarf
 bei Schutzimpfungen
 – Literaturverzeichnis –

Stand: Januar 2004



- Village, IL; American Academy of Pediatrics 2000, p 435.
- 13 American Academy of Pediatrics. Tetanus. In: Pickering LK, ed. 2000 Red Book: Report of the Committee on Infectious Diseases. 25th ed. Elk Grove Village, IL; American Academy of Pediatrics 2000, p 563.
 - 14 Dittmann S. Diphtheria vaccine (including diphtheria-tetanus vaccine. In: Meyler's Side Effect of Drugs (eds. Dukes MNG, Aronson JK). Elsevier, Amsterdam 2000, pp 1064–1065.
 - 15 Chen RT, Mootrey G, DeStefano F. Safety of routine childhood vaccinations: An epidemiological review. *Pediatr Drugs* 2000; 2. section DTP vaccines, pp 277–280.
 - 16 Supplementary information on vaccine safety – Background rates of adverse events following immunization. Section Adverse events following DTP vaccines. World Health Organization, Geneva 2000. WHO/V&B/00.36, pp 17–25.
 - 17 Dittmann S. Combination vaccines: DTaP or DTwP vaccine combined with other antigens, such as Hib, IPV, and hepatitis B vaccine, or simultaneous administration of these vaccines. In: Side Effects of Drugs Annual 25 (ed Aronson JK). Elsevier, Amsterdam 2002, p 382–384.
 - 18 Dittmann S. Diphtheria/tetanus or diphtheria/tetanus/pertussis vaccines in combination with other vaccines. In: Side Effects of Drugs Annual 26 (ed Aronson JK). Elsevier, Amsterdam 2003, p 356–357.
 - 19 WHO Information bank: Adverse events following diphtheria, tetanus and pertussis vaccines. >www.who.int/vaccines-diseases/safety/infobank/dtp.shtml< (Zugang: August 2, 2003)

Ferner in Abhängigkeit von den neben DTaP im Impfstoff enthaltenen weiteren Komponenten (Haemophilus influenzae [Hib] und/oder Poliomyelitis [inaktiviert-IPV] und/oder Hepatitis B) diesbezügliche Literaturangaben.

Literatur zur Sicherheit und Wirksamkeit von Kombinations- und Mehrfachimpfungen

- 20 Decker MD, Edwards KM. Combination vaccines. In: Plotkin SA, Orenstein WA (eds). Vaccines. Saunders, Philadelphia 1999, pp 508–530.
- 21 Offit PA, Quarles J, Gerber MA, Hackett ChJ, Marcuse EK, Kollman TR, Gellin BG, Landry S. Addressing parent's concerns: Do multiple vaccines overwhelm or weaken the infant's immune system? *Pediatrics* 2002; 109(1): 124–129.
- 22 Institute of Medicine (IOM) Report. Immunizations Safety Review: Multiple immunizations and immune dysfunction. 2002 (Zugang 26 Februar 2003) >http://www.cdc.gov/nip/vacsafe/concerns/gen/multiplevac_iom.htm<
- 23 Halsey NA. Safety of combination vaccines: perception versus reality. *Pediatr Infect Dis J* 2001; 20 (Suppl. 1): S40–S44.

Literatur zu Impfungen und plötzlichem Kindstod (sudden infant death syndrome – SIDS)

- 24 Institute of Medicine (IOM) Report. Immunizations Safety Review. Vaccinations and sudden unexpected death in infancy. The National Academies Press 2003. ><http://www.nap.edu/nap-cgi/>< (Zugang: 20 Juni 2003).
- 25 Fleming PJ et al. The UK accelerated immunization programme and sudden unexpected death in infancy: case-control study. *Brit Med J* 2001; 322: 822–825
- 26 Keller-Stanislawski B, Löwer J. Todesfälle im zeitlichen Zusammenhang mit Sechsfachimpfung. *Kinder- und Jugendarzt* 2003; 34: 608.
- 26a Die Europäische Arzneimittelagentur (EMA) sieht unverändertes Nutzen/Risikoprofil für Sechsfachimpfstoffe. >http://www.pei.de/professionals/hexavalente_nov.pdf< (Zugang 2.12.03)
- 26b EMA. Public Statement – December 1, 2003. ><http://www.emea.eu.int/pdfs/human/press/pus/588903en.pdf>< (Zugang 2.12.03)

FSME-Impfstoff

- 27 Quast U, Thilo W, Fescharek R. Impfreaktionen – Bewertung und Differentialdiagnose. 2. Auflage. Hippokrates, Stuttgart 1997. Kapitel Frühsommer-Meningoenzephalitis, S. 44–48.
- 28 Barret PN, Dorner F, Plotkin SA. Tick-Borne Encephalitis vaccine. In: Plotkin SA, Orenstein WA (eds). Vaccines. 3rd edition. Saunders, Philadelphia 1999, 767–780.
- 29 Supplementary information on vaccine safety – Background rates of adverse events following immunization. Section Adverse events following tick-borne encephalitis virus vaccine. World Health Organization, Geneva 2000. WHO/V&B/00.36, pp 87–88.
- 30 World Health Organization. Adverse events following tick-borne encephalitis (TBE) virus vaccine. ><http://www.who.int/vaccines-diseases/safety/infobank/tbe.shtml>< (Zugang: 3 Februar 2003)

Gelbfieber-Impfstoff

- 31 WHO. Prevention and Control of Yellow Fever in Africa. WHO, Geneva, 1986.
- 32 Merlo C, Steffen R, Landis T, Tsai T. Possible association of encephalitis and 17D yellow fever vaccination in a 29-year-old traveller. *Vaccine* 1993; 11: 691.
- 33 Drouet A, Chagnon A, Valance J, CarliP, Muzellec Y, Paris YF. Meningoencephalitis after immunization with 17D yellow fever virus. *Rev Med Interne* 1993; 14: 257–259.
- 34 Quast U, Thilo W, Fescharek R. Impfreaktionen – Bewertung und Differentialdiagnose. 2. Auflage. Hippokrates, Stuttgart 1997. Kapitel Gelbfieber, S. 49–52

- 35 Monath TP. Yellow Fever. In: Plotkin SA, Orenstein WA (eds). *Vaccines*. 3rd edition. Saunders, Philadelphia 1999, 815–879.
- 36 Supplementary information on vaccine safety – Background rates of adverse events following immunization. Section Adverse events following yellow fever vaccine. World Health Organization, Geneva 2000. WHO/V&B/00.36, pp 102–105.
- 37 Dittmann S. Yellow fever vaccine. In: *Meyler's Side Effect of Drugs* (eds. Dukes MNG, Aronson JK). Elsevier, Amsterdam 2000, pp 1097–1098.
- 38 Mitteilung der Ständigen Impfkommision (STIKO) am Robert Koch-Institut: Zu Nebenwirkungen und vereinzelt Komplikationen nach Gelbfieberimpfung. RKI, *Epid Bull* 2001; 44: 336–337.
- 39 Yellow fever vaccine. Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2002. *Morbidity and Mortality Weekly Report* 2002; 51: RR-17.
- 40 Adverse events associated with 17D-derived yellow fever vaccination – United States, 2001–2002. *Morbidity and Mortality Weekly Report* 2002; 51: 989–993.
- 41 World Health Organization. Adverse events following yellow fever vaccine.
><http://www.who.int/vaccines-diseases/safety/infobank/Yellfev.shtml>< (Zugang: 3 Februar 2003)
- 50 Trampisch HJ, Lange S. Diabetes mellitus nach Hib-Impfung? Die Diskussion geht weiter. *Kinderärztl Prax* 2000; 71: 6–10.
- 51 World Health Organization. Adverse events following Haemophilus influenzae type b (Hib) vaccine.
><http://www.who.int/vaccines-diseases/safety/infobank/hib.shtml>< (Zugang: 3 Feb 2003)

Haemophilus-influenzae-Impfstoff

- 42 Stratton KR, Howe CJ, Johnston RB Jr, eds. Adverse events associated with childhood vaccines. National Academy of Sciences: Washington, DC, 1994, section Haemophilus influenzae Type b Vaccines, pp 236–273.
- 43 Quast U, Thilo W, Fescharek R. Haemophilus Impfreaktionen – Bewertung u. Differentialdiagnose. 2. Auflage. Hippokrates, Stuttgart 1997. Kapitel Haemophilus influenzae Typ b (Hib)-Erkrankung, S. 53–56.
- 44 Von Kries R, Schmitt HJ. Diabetes mellitus nach Hib-Impfung? *Kinderärztl Prax* 1999; 70: 589–590.
- 45 Ward JI, Zangwill KM. Haemophilus influenzae vaccines. In: Plotkin SA, Orenstein WA (eds). *Vaccines*. 3rd edition. Saunders, Philadelphia 1999, 183.
- 46 Dittmann S. Haemophilus influenzae vaccines (including combination vaccines with Hib component). In: *Meyler's Side Effect of Drugs* (eds. Dukes MNG, Aronson JK). Elsevier, Amsterdam 2000, pp 1065–1066.
- 47 Supplementary information on vaccine safety – Background rates of adverse events following immunization. Section Adverse events associated with Haemophilus influenzae type b (Hib) vaccine. World Health Organization, Geneva 2000. WHO/V&B/00.36, pp 26–30.
- 48 American Academy of Pediatrics. Haemophilus influenzae infections. In: Pickering LK, ed. 2000 Red Book: Report of the Committee on Infectious Diseases. 25th ed. Elk Grove Village, IL; American Academy of Pediatrics 2000: 262.
- 49 Chen RT, Mootrey G, DeStefano F. Safety of routine childhood vaccinations: An epidemiological review.

- Pediatr Drugs 2000; 2: section Haemophilus influenzae Type B Vaccines, pp 281–282.

Haemophilus-influenzae-/Hepatitis-B-Impfstoff

Siehe Literaturangaben bei Hib- und Hepatitis-B-Impfstoffen.

Hepatitis-A-Impfstoff

- 52 Quast U, Thilo W, Fescharek R. Impfreaktionen – Bewertung und Differentialdiagnose. 2. Auflage. Hippokrates, Stuttgart 1997. Kapitel Hepatitis A, S 57–59.
- 53 Feinstone SM, Gust ID. Hepatitis A vaccine. In: Plotkin SA, Orenstein WA (eds) *Vaccines*. 3rd edition. Saunders, Philadelphia 1999, 650–671.
- 54 Supplementary information on vaccine safety – Background rates of adverse events following immunization. Section Adverse events following hepatitis A vaccine. World Health Organization, Geneva 2000. WHO/V&B/00.36, pp 11–33.
- 55 World Health Organization. Adverse events following hepatitis A vaccine.
><http://www.who.int/vaccines-diseases/safety/infobank/hav.shtml>< (Zugang: 3 Feb 2003).

Hepatitis-B-Impfstoff

- 56 Stratton KR, Howe CJ, Johnston RB Jr, eds. Adverse events associated with childhood vaccines. National Academy of Sciences: Washington, DC, 1994, section hepatitis B vaccines, pp 211–235.
- 57 Recommendations of the Advisory Committee on Immunization Practices (ACIP). Update: Vaccine side effects, adverse reactions, contraindications, and precautions. *Morbidity and Mortality Weekly Report* 1996; 45: No RR-12, section hepatitis B vaccine side effects and adverse reactions, p 7.
- 58 Quast U, Thilo W, Fescharek R. Impfreaktionen – Bewertung und Differentialdiagnose. 2. Auflage. Hippokrates, Stuttgart 1997. Kapitel Hepatitis B, S 60–66.
- 59 Mahoney FJ, Kane M. Hepatitis B vaccine. In: Plotkin SA, Orenstein WA (eds) *Vaccines*. 3rd edition. Saunders, Philadelphia 1999, 158
- 60 American Academy of Pediatrics. Hepatitis B. In: Pickering LK, ed. 2000 Red Book: Report of the Committee on Infectious Diseases. 25th ed. Elk Grove Village, IL; American Academy of Pediatrics 2000: 289.
- 61 Dittmann S. Hepatitis B vaccine. In: *Meyler's Side Effect of Drugs* (eds. Dukes MNG, Aronson JK). Elsevier, Amsterdam 2000, pp 1067–1071.

- 62 Chen RT, Mootrey G, DeStefano F. Safety of routine childhood vaccinations: An epidemiological review. *Pediatr Drugs* 2000; 2: section Hepatitis B Vaccines, pp 282–283.
- 63 Supplementary information on vaccine safety – Background rates of adverse events following immunization. Section adverse events associated with the hepatitis B vaccine. World Health Organization, Geneva 2000. WHO/V&B/00.36, pp 34–39.
- 64 Hartmann K, Keller-Stanislawski B. Rekombinante Hepatitis B-Impfstoffe und Verdachtsfälle unerwünschter Reaktionen. *Bundesgesundheitsbl – Gesundheitsforsch – Gesundheitsschutz* 2002; 45: 355–363.
- 65 World Health Organization. Adverse events following hepatitis B vaccine.
><http://www.who.int/vaccines-diseases/safety/infobank/hbv.shtml>< (Zugang: 3 Feb 2003)
- 66 World Health Organization. Questions and answers about hepatitis B infection and vaccine.
><http://www.who.int/vaccines-diseases/safety/infobank/HepatitisB.shtml>< (Zugang: 3 Feb 2003)
- Hepatitis-B-Impfstoff und multiple Sklerose**
- 67 Anonymous. *Wkly Epidemiol Rec* 1997; 72: 149–52.
- 68 Medical Advisory Board of the National Multiple Sclerosis Society: Statement from 14 August 1998. National Multiple Sclerosis Society: News Desk Research Bulletins, 3 September 1998.
- 69 Zipp F. No increase in demyelinating disease after hepatitis B vaccination. *Nature Medicine* 1999; 519: 964–965.
- 70 Fourrier A, Touze E, Alperovitch A, Begaud B. Association between hepatitis B vaccine and multiple sclerosis: a case-control study. *Pharmacoepidemiol Drug Safety* 1999; 8: 140–141.
- 71 Sturkenboom MCJM, Abenhaim L, Wolfson C, Roulet E, Heinzelf O, Gout O. Vaccinations. Demyelination, and multiple sclerosis study (VDAMS). *Pharmacoepidemiol Drug Safety* 1999; 8: 170–171.
- 72 Sadvnik AD, Scheifele DW. School-based hepatitis B vaccination programme and adolescent multiple sclerosis. *Lancet* 2000; 355: 549–550.
- 73 Chen RT, Mootrey G, DeStefano F. Safety of routine childhood vaccinations: An epidemiological review. *Pediatr Drugs* 2000; 2: 282–283.
- 74 Dittmann S. Vaccines. In: Dukes MNG, editor. *Meyler's Side Effects of Drugs*, 14th edition. Elsevier, Amsterdam, 2000: 1067–1071.
- 75 American Academy of Pediatrics. Hepatitis B. In: Pickering LK, ed. 2000 Red Book: Report of the Committee on Infectious Diseases. 25th ed. Elk Grove Village, IL; American Academy of Pediatrics 2000: 289.
- 76 Touzé E, Gout O, Verdier-Taillefer, Lyon-Caen O, Alperovitch A. Premier épisode de Démyélinisation du système nerveux central et vaccination contre l'hépatite B. *Rev Neurol (Paris)* 2000; 156: 242–246.
- 77 Monteyne P, André FE. Is there a causal link between hepatitis B vaccination and multiple sclerosis? *Vaccine* 2000; 18: 1994–2001.
- 78 Gellin BG, Schaffner W. The risk of vaccination – the importance of 'negative' studies. *N Engl J Med* 2001; 344: 372–373.
- 79 Asherio A, Zhang SM, Hernan MA, Olek MJ, Coplan PM, Brodovicz K, Walker AM. Hepatitis B vaccination and the risk of multiple sclerosis. *N Engl J Med* 2001; 344: 327–332.
- 80 Confavreux C, Suissa S, Saddier P, Bourdes V, Vucusic S. Vaccinations and the risk of relapse in multiple sclerosis. *Vaccines in multiple sclerosis study group. N Engl J Med* 2001; 319–326.
- 81 Hostetler L. Vaccinations and multiple sclerosis. *N Engl J Med* 2001; 344: 1795.
- 82 WHO Information bank: Questions and answers about hepatitis B infection and vaccine.
>www.who.int/vaccines-diseases/safety/infobank/HepatitisB.shtml< (Zugang 3 Januar 2003)
- 83 WHO – Information bank: Adverse events associated with Hepatitis B vaccine.
>www.who.int/vaccines-diseases/safety/infobank/hbv.shtml< (Zugang 3 Januar 2003)
- 84 Institute of Medicine. Report – Hepatitis B vaccine and demyelinating neurological disorders.
><http://www.cdc.gov/nip/news/iom-hepb-5-2002/iom.htm>< (Zugang: 3 Feb 2003)
- Hepatitis-A-/Hepatitis-B-Impfstoff**
- Siehe Literaturangaben bei Hepatitis-A- und Hepatitis-B-Impfstoffen.
- Influenza-Impfstoff**
- 85 Quast U, Thilo W, Fescharek R. *Impfreaktionen – Bewertung und Differentialdiagnose*. 2. Auflage. Hippokrates, Stuttgart 1997. Kapitel Influenza, S 67–72.
- 86 Kilbourne ED, Arden NH. Inactivated influenza vaccines. In: Plotkin SA, Orenstein WA (eds). *Vaccines*. 3rd edition. Saunders, Philadelphia 1999, 531–552.
- 87 Dittmann S. Vaccines. In: *Meyler's Side Effect of Drugs* (eds. Dukes MNG, Aronson JK). Elsevier, Amsterdam 2000, pp 1072–1075.
- 88 Supplementary information on vaccine safety – Background rates of adverse events following immunization Section Adverse events following influenza vaccine. World Health Organization, Geneva 2000. WHO/V&B/00.36, pp 40–44.
- 89 World Health Organization. Adverse events following influenza vaccine.
><http://www.who.int/vaccines-diseases/safety/infobank/influenza.shtml>< (Zugang: 3 Feb 2003)

Masern-Impfstoff

- 90 Stratton KR, Howe CJ, Johnston RB Jr, eds. Adverse events associated with childhood vaccines. National Academy of Sciences: Washington, DC, 1994, section measles and mumps vaccines, pp 118–186.
- 91 Recommendations of the Advisory Committee on Immunization Practices (ACIP). Update: Vaccine side effects, adverse reactions, contraindications, and precautions. *Morbidity and Mortality Weekly Report* 1996; 45: No RR-12, section measles vaccine side effects and adverse reactions, p 10.
- 92 Quast U, Thilo W, Fescharek R. Impfreaktionen – Bewertung und Differentialdiagnose. 2. Auflage. Hippokrates, Stuttgart 1997. Kapitel Masern, S 77–82.
- 93 Duclos P, Ward BJ. Measles vaccines. A review of adverse events. *Drug Safety* 1998; 19: 435–454.
- 94 Redd SC, Markowitz LF, Katz SL. Measles vaccine. In: Plotkin SA, Orenstein WA (eds). *Vaccines*. 3rd edition. Saunders, Philadelphia 1999, 222–267.
- 95 Dittmann S. Measles vaccine. In: *Meyler's Side Effect of Drugs* (eds. Dukes MNG, Aronson JK). Elsevier, Amsterdam 2000, pp 1076–1078.
- 96 Hartmann K, Keller-Stanislawski B. Verdachtsfälle unerwünschter Arzneimittelnebenwirkungen nach Anwendung von Impfstoffen mit attenuierter Masernkomponente. *Bundesgesundheitsblatt – Gesundheitsforsch – Gesundheitsschutz* 2001; 44: 981–986.
- 97 Thompson NP, Montgomery SM, Pounder RE, Wakefield AJ. Is measles vaccination a risk factor for inflammatory bowel disease? *Lancet* 1995; 345: 1071–1074.
- 98 Wakefield AJ, Murch SH, Linnell AAJ, Casson DM, Malik M, Bewrelowitz M. Ileal-lymphoid-nodular hypoplasia, non-specific colitis and pervasive developmental disorder in children. *Lancet* 1998; 351: 637–641.
- 99 Uhlmann V, Martin CM, Sheils O, Pilkington L, Silva I, Killalea A, Murch SB, Wakefield AJ, O'Leary JJ. Potential viral pathogenic mechanism for new variant inflammatory bowel disease. *Molecular Pathology* 2002; 55: 1–6.
- 100 Haga Y, Funagoshi O, Kuroe K et al. Absence of measles viral genomic sequences in intestinal tissues from Crohn's disease by nested polymerase chain reaction. *Gut* 1996; 38: 211–215.
- 101 Wing L. Autism spectrum disorders: no evidence for or against an increase in prevalence. *Br Med J* 1996; 312: 327–328.
- 102 Fisher NC, Yee L, Nightingale P et al. Measles virus serology in Crohn's disease. *Gut* 1997; 41: 66–69.
- 103 Gilat T, Hacoheh D, Lilos P et al. Childhood factors in ulcerative colitis and Crohn's disease. *Scand J Gastroenterol* 1997; 22: 1009–24.
- 104 Payne Ch, Mason B. Letter to the editor. *Lancet* 1998; 351: 907.
- 105 Nielsen LLW, Nielsen NM, Melbye M et al. Exposure to measles in utero and Crohn's disease: a Danish register study. *Br Med J* 1998; 316: 196–197.
- 106 Peltola H, Patja A, Leinikki P, Valle M, Davidkin I, Pautio M. No evidence for measles, mumps, and rubella vaccine-associated inflammatory bowel disease or autism in a 14-year prospective study. *Lancet* 1998; 351: 1327–1328.
- 107 Yamashita Y, Walker-Smith A, Shimizu T, Oguchi S, Ohtsuka Y. Measles vaccination and inflammatory bowel disease in Japanese children. Letter to the editor. *J Pediatr Gastroenterol Nutr* 1998; 26: 238.
- 108 Taylor B, Miller E, Farrington CP, Petropoulos MC, Favot-Mayaud I, Jun Li, Waight PA. Autism and measles, mumps, and rubella vaccine: no epidemiological evidence for a causal association. *Lancet* 1999; 353: 2026–2029.
- 109 Dittmann S. Vaccines. In: Dukes MNG, editor. *Meyler's Side Effects of Drugs*, 14th edition. Elsevier, Amsterdam, 2000: 1092–1093.
- 110 Chen RT, Mootrey G, DeStefano F. Safety of routine childhood vaccinations: An epidemiological review. *Pediatr Drugs* 2000; 2: 283–285.
- 111 Patja A, Davidkin I, Kurki T, Kallio MJT, Valle M, Peltola H. Serious adverse events after measles-mumps-rubella vaccination during a fourteen-year prospective follow-up. *Pediatr Infect Dis J* 2000; 19: 1127–1134.
- 112 Halsey NA, Hyman SL, and the conference writing panel. Electronic article: Measles-mumps-rubella vaccine and autistic spectrum disorder: Report from the new challenges in childhood immunizations conference convened in Oak Brook, Illinois, June 12–13, 2000. *Pediatrics* 2001; 107: e84.
- 113 Arlett P, Bryan P. Adverse Drug React Toxicol Rev 2001; 20 (1): 37–45.
- 114 Morris A, Aldulaimi D. New evidence for a viral pathogenic mechanism for a new variant inflammatory bowel disease and development disorder? *Molecular Pathology* 2002; 55: 83.
- 115 World Health Organization. Crohn's disease. WHO position statement.
><http://www.who.int/vaccines-diseases/safety/infobank/crohn.shtml> (Zugang: 3 Feb 2003)
- 116 World Health Organization. Autism and measles containing vaccines: how the press reported it.
><http://www.who.int/vaccines-diseases/safety/infobank/autism.html> (Zugang: 3 Feb 2003)
- 117 WHO – Vaccines, Immunization and Biologicals: MMR and autism.
>www.who.int/vaccines-diseases/safety/hotspot/mmr-statement.shtml (Zugang: 1 Januar, 2003)
- 118 UK Medical Research Council Review of autism research, epidemiology and causes. December 2001.
><http://www.mrc.ac.uk/txt/pdf-autism-report.pdf> (Zugang: 1 Januar 2003)
- 119 Taylor B, Miller E, Lingam R, Andrews N, Simmons A, Stowe J. Measles, mumps, and rubella vaccination and bowel problems or developmental regression in child-

Masern-Impfstoff und Autismus sowie Morbus Crohn

- ren with autism: population study. *Brit Med J* 2002; 324: 393–396
- 120 Institute of Medicine Immunization Safety Reviews: Measles-mumps-rubella vaccine and autism report. National Academy Press, Washington DC 2001. March 2002.
><http://www.cdc.gov/nip/news/iom-04-24.htm>< (Zugang: 3 Feb 2003)
- 121 US Centres for Disease Control website. Vaccines and autism – references.
><http://www.cdc.gov/nip/vacsafe/concerns/autism/autism-ref.htm>< (Zugang: 1 Januar 2003)
- 122 US Centres for Disease Control website. Measles vaccine and inflammatory bowel disease – references.
><http://www.cdc.gov/nip/vacsafe/concerns/autism/ibd.htm>< (Zugang: 1 Januar 2003)

Mumps-Impfstoff

- 123 Deutsche Vereinigung zur Bekämpfung der Viruskrankheiten (DVV). Mumpsschutzimpfung und Diabetes mellitus (Typ I). *Bundesgesundheitsblatt* 1989; 32: 237.
- 124 Stratton KR, Howe CJ, Johnston RB Jr, eds. Adverse events associated with childhood vaccines. National Academy of Sciences: Washington, DC, 1994, section measles and mumps vaccines, pp 118–186.
- 125 Recommendations of the Advisory Committee on Immunization Practices (ACIP). Update: Vaccine side effects, adverse reactions, contraindications, and precautions. *Morbidity and Mortality* 1996; 45: No RR-12, section mumps vaccine adverse effects of vaccine use, p 19.
- 126 Quast U, Thilo W, Fescharek R. *Impfreaktionen – Bewertung und Differentialdiagnose*. 2. Auflage. Hippokrates, Stuttgart 1997. Kapitel Mumps, S 87–93.
- 127 Plotkin SA, Wharton M. Mumps vaccine. In: Plotkin SA, Orenstein WA (eds) *Vaccines*. 3rd edition. Saunders, Philadelphia 1999, 267–292.
- 128 Dittmann S. Mumps vaccine. In: Meyler's Side Effect of Drugs (eds. Dukes MNG, Aronson JK). Elsevier, Amsterdam 2000, pp 1080–1083.
- 132 Supplementary information on vaccine safety – Background rates of adverse events following immunization. Section measles, mumps and rubella vaccine. World Health Organization, Geneva 2000. WHO/V&B/00.36, pp 55–68.
- 133 Dittmann S. Measles-mumps-rubella (MMR) vaccine. In: Meyler's Side Effect of Drugs (eds. Dukes MNG, Aronson JK). Elsevier, Amsterdam 2000, pp 1078–1080.
- 134 Chen RT, Mootrey G, DeStefano F. Safety of routine childhood vaccinations: An epidemiological review. *Pediatric Drugs* 2000; 2: section MMR vaccination, pp 283–284.
- 135 Plesner AM, Hansen FJ, Taudorf K, Nielsen LH, Larsen CB. Gait disturbance interpreted as cerebellar ataxia after MMR vaccination at 15 months of age: a follow-up study. *Acta Paediatr* 2000; 89: 58–63.
- 136 Hartmann K, Keller-Stanislawski B. Verdachtsfälle unerwünschter Arzneimittelnebenwirkungen nach Anwendung von Impfstoffen mit attenuierter Masernkomponente. *Bundesgesundheitsblatt – Gesundheitsforsch – Gesundheitsschutz* 2001; 44: 981–986.
- 137 Miller E, Waight P, Farrington P, Andrews N, Stowe J, Taylor B. Idiopathic thrombocytopenic purpura and MMR vaccine. *Arch Dis Child* 2001; 84: 221–229
- 138 Global Advisory Committee on Vaccine Safety. MMR and autism. *Weekly Epidemiol Rec* 2002; 78: 18–19.
- 139 Dittmann S. measles-mumps-rubella (MMR) vaccine, including MMR and autism and Crohn's disease. In: *Side Effects of Drugs Annual 25* (ed Aronson JK). Elsevier, Amsterdam 2002, pp 387–389.
- 140 World Health Organization. Adverse events following measles, mumps, and rubella vaccines.
><http://www.who.int/vaccines-diseases/safety/info-bank/mmr.shtml>< (Zugang: 3 Feb 2003)
- 141 World Health Organization. Adverse events following measles, mumps, and rubella vaccines.
><http://www.who.int/vaccines-diseases/safety/info-bank/mmrnew.doc>< (Zugang: 3 Feb 2003)

Masern-Mumps-Impfstoff

- 129 Stratton KR, Howe CJ, Johnston RB Jr, eds. Adverse events associated with childhood vaccines. National Academy of Sciences: Washington, DC, 1994, section measles and mumps vaccines, pp 118–186.
- 130 Fescharek R, Quast U, Maass G, Merkle W, Schwarz S. Measles-mumps vaccination in the FRG: an empirical analysis after 14 years of use. II. Tolerability and analysis of spontaneously reported side effects. *Vaccine* 1990; 8: 446–456.

MMR-Impfstoff

- 131 Stratton KR, Howe CJ, Johnston RB Jr, eds. Adverse events associated with childhood vaccines. National

Meningokokken-(Polysaccharid)-Impfstoff

- 142 Quast U, Thilo W, Fescharek R. *Impfreaktionen – Bewertung und Differentialdiagnose*. 2. Auflage. Hippokrates, Stuttgart 1997. Kapitel Meningokokken-Erkrankung, S 83–86.
- 143 Lepow ML, Perkins BA, Hughes PA, Poolman JD. Meningococcal vaccines. In: Plotkin SA, Orenstein WA (eds) *Vaccines*. 3rd edition. Saunders, Philadelphia 1999, 711–727.
- 144 Dittmann S. Meningococcal vaccine. In: Meyler's Side Effect of Drugs (eds. Dukes MNG, Aronson JK). Elsevier, Amsterdam 2000, p 1080.
- 145 Supplementary information on vaccine safety – Background rates of adverse events following immunization. Section Adverse events following meningococcal

- polysaccharide vaccine. World Health Organization, Geneva 2000. WHO/V&B/00.36, pp 51–54.
- 146 World Health Organization. Adverse events following meningococcal polysaccharide vaccine. ><http://www.who.int/vaccines-diseases/safety/info-bank/mening.shtml>< (Zugang: 3 Feb 2003)
- 147 Meningococcal vaccines: polysaccharide and polysaccharide conjugate vaccines. WHO position paper. *Weekly Epidemiol Rec* 2002; 77: 331–339.
- 158 Supplementary information on vaccine safety – Background rates of adverse events following immunization. Section Adverse events following pneumococcal vaccine. World Health Organization, Geneva 2000. WHO/V&B/00.36. pp 69–71.
- 159 Dittmann S. Pneumococcal vaccine. In: Meyler's Side Effect of Drugs (eds. Dukes MNG, Aronson JK). Elsevier, Amsterdam 2000, pp 1086–1087.
- 160 American Academy of Pediatrics. Pneumococcal infections. In: Pickering LK, ed. 2000 Red Book: Report of the Committee on Infectious Diseases. 25th ed. Elk Grove Village, IL; American Academy of Pediatrics 2000: 452.

Meningokokken-(Konjugat)-Impfstoff

- 148 Richmond P, Goldblatt D, Fusco PC, Fusco DJS, Heron I. Safety and immunogenicity of a new *Neisseria meningitidis* serogroup C tetanus conjugate vaccine in healthy adults. *Vaccine* 1999; 18: 641–646.
- 149 MacLennan JM, Shackley F, Heath PT, Deeks JJ, Flammank C, Herbert M, Griffiths H, Hatzmann E, Goilav C, Moxon ER. Safety, immunogenicity, and induction of immunologic memory by a serogroup C meningococcal conjugate vaccine in infants. *J Am Med Assoc* 2000; 283: 2795–2801
- 150 Dittmann S. Meningococcal vaccine. In: Side Effects of Drugs Annual 25 (ed Aronson JK) Elsevier, Amsterdam 2002, p 381.
- 151 Meningococcal vaccines: polysaccharide and polysaccharide conjugate vaccines. WHO position paper. *Weekly Epidemiol Rec* 2002; 77: 331–339. ><http://www.who.int/vaccines-diseases/safety/info-bank/mening.shtml>< (Zugang: 3 Feb 2003)
- 152 Dittmann S. Meningokokken-Erkrankungen. Thieme, Stuttgart 2003
- 152a Abeyagunawardena AS, Goldblatt D, Andrews N, Trompeter RS. Risk of relapse after meningococcal conjugate vaccine in nephritic syndrome. *Research letter. Lancet* 2003; 362: 449–450.
- 161 Overturf GD, Peter G, Pickering LK, MacDonald NE, Chilton L, Jacobs RF, Delage G, Dowell SF, Orenstein WA, Patriarca PA, Myers MG, Ledbetter EO, Kim J. Technical report: Prevention of pneumococcal infections, including the use of pneumococcal conjugate and polysaccharide vaccines and antibiotic prophylaxis. *Pediatrics* 2000; 106: 367–376.
- 162 World Health Organization. Adverse events following pneumococcal vaccine. ><http://www.who.int/vaccines-diseases/safety/info-bank/pneumo.shtml>< (Zugang: 3 Feb 2003)

Pneumokokken-(Konjugat)-Impfstoff

- 163 Fedson DS, Musher DM, Eskola J. Pneumococcal vaccine. In: Plotkin SA, Orenstein WA (eds). *Vaccines*. 3rd edition. Saunders, Philadelphia 1999, 553–608.
- 164 Shinefield HR, Black S, Ray P, Chang I, Lewis N, Fireman B, Hackell J, Paradiso PR, Siber G, Kohberger R, Madore DV, Malinowski FJ, Kimura A, Le C., Landaw I, Aguilar J, Hansen J. Safety and immunogenicity of heptavalent pneumococcal CRM197 conjugate vaccine in infants and toddlers. *Pediatr Infect Dis J* 1999; 18: 757–63.
- 165 American Academy of Pediatrics. Pneumococcal infections. In: Pickering LK, ed. 2000 Red Book: Report of the Committee on Infectious Diseases. 25th ed. Elk Grove Village, IL; American Academy of Pediatrics 2000: 452.
- 166 Black S, Shinefield H, Fireman B, Lewis E, Ray P, Hansen JR, Elvin L, Ensor KM, Hackell J, Siber G, Malinowski F, Madore D, Chang I, Kohberger R, Watson W, Austrian R, Edwards K, Aguilar J, Bartlett M, Bergen R, Burman M, Dorfman S, Easter W, Finkel A, Froehlich H, Glauber J, Herz A, Honeychurch D, Kleinrock R, and the Northern California Kaiser Permanente Vaccine Study Center group. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. *Pediatr Infect Dis J* 2000; 19: 187–195.
- 167 Dittmann S. Pneumococcal vaccine. In: Meyler's Side Effect of Drugs (eds. Dukes MNG, Aronson JK). Elsevier, Amsterdam 2000, pp 1086–1087
- 168 Dabelstein D, Cromer B. Recent advances in conjugated pneumococcal Vaccination. *Fam Pract* 2000; 17: 435–441.
- 153 Quast U, Thilo W, Fescharek R. Impfreaktionen – Bewertung und Differentialdiagnose. 2. Auflage. Hippokrates, Stuttgart 1997. Kapitel Pertussis, S 94–99.
- 154 Edwards KM, Decker MD, Mortimer Jr EA. Pertussis vaccine. 293–344. In: Plotkin SA, Orenstein WA (eds). *Vaccines*. 3rd edition. Saunders, Philadelphia 1999, 140.
- 155 Dittmann S. Acellular pertussis vaccine. In: Meyler's Side Effect of Drugs (eds. Dukes MNG, Aronson JK). Elsevier, Amsterdam 2000, pp 1085–1086.

Pertussis-Impfstoff, azellulär

Pneumokokken-(Polysaccharid)-Impfstoff

- 156 Quast U, Thilo W, Fescharek R. Impfreaktionen – Bewertung und Differentialdiagnose. 2. Auflage. Hippokrates, Stuttgart 1997. Kapitel Pneumokokkenerkrankung, S 100–103.
- 157 Fedson DS, Musher DM, Eskola J. Pneumococcal vaccine. In: Plotkin SA, Orenstein WA (eds). *Vaccines*. 3rd edition. Saunders, Philadelphia 1999, 553–608.

- 169 Overturf GD, Peter G, Pickering LK, MacDonald NE, Chilton L, Jacobs RF, Delage G, Dowell SF, Orenstein WA, Patriarca PA, Myers MG, Ledbetter EO, Kim J. Technical report: Prevention of pneumococcal infections, including the use of pneumococcal conjugate and polysaccharide vaccines and antibiotic prophylaxis. *Pediatrics* 2000; 106: 367–376.
- 170 Schmöle-Thoma B. 7-valenter Konjugatimpfstoff Prevenar: Immunogenität, Reaktogenität und Wirksamkeit. *Kinderärztl Prax* 2001; 72, Sonderheft Pneumokokkenimpfung: S 16–21
- 171 Kalies H, Hermann M, Schmitt HJ, von Kries R. Prävention invasiver Pneumokokkeninfektionen im Kindesalter. *Kinderärztl Prax* 2001; 72: 31–36.
- 172 Volz S, Habermehl P, Zell A, Knuf M. Pneumokokken und Pneumokokkenimpfstoffe: Bedeutung für die Pädiatrie. *Monatsschr Kinderheilkunde* 2001; 149: 394–409.

Poliomyelitis-Impfstoff (inaktiviert – IPV)

- 173 Stratton KR, Howe CJ, Johnston RB Jr, eds. Adverse events associated with childhood vaccines. National Academy of Sciences: Washington, DC, 1994, section polio vaccines, pp 187–210.
- 174 Recommendations of the Advisory Committee on Immunization Practices (ACIP).
- 175 Update: Vaccine side effects, adverse reactions, contraindications, and precautions. *Morbidity and Mortality Weekly Report* 1996; 45: No RR-12, section poliomyelitis vaccine adverse reaction, p 8.
- 176 Quast U, Thilo W, Fescharek R. Impfreaktionen – Bewertung und Differentialdiagnose. 2. Auflage. Hippokrates, Stuttgart 1997. Kapitel Poliomyelitis, S 104–111.
- 177 Plotkin SA, Wharton M. Inactivated polio vaccine. In: Plotkin SA, Orenstein WA (eds). *Vaccines*. 3rd edition. Saunders, Philadelphia 1999, 345.
- 178 American Academy of Pediatrics. Poliovirus infections. In: Pickering LK, ed. 2000 Red Book: Report of the Committee on Infectious Diseases. 25th ed. Elk Grove Village, IL; American Academy of Pediatrics 2000: 465.
- 179 Dittmann S. Poliomyelitis vaccine. In: *Meyler's Side Effect of Drugs* (eds. Dukes MNG, Aronson JK). Elsevier, Amsterdam 2000, pp 1087–1090.
- 180 Chen RT, Mootrey G, DeStefano F. Safety of routine childhood vaccinations: An epidemiological review. *Pediatr Drugs* 2000; 2: section inactivated and oral poliovirus vaccines, pp 280–281.
- 181 Supplementary information on vaccine safety – Background rates of adverse events following immunization. Section Adverse events following poliomyelitis vaccine. World Health Organization, Geneva 2000. WHO/V&B/00.36, pp 72–78.
- 182 World Health Organization. Adverse events following poliomyelitis vaccine.
><http://www.who.int/vaccines-diseases/safety/infobank/polio.shtml>< (Zugang: 3 Feb 2003)

Röteln-Impfstoff

- 183 Howson CP, Howe CJ, Fineberg HV, eds. Adverse effects of pertussis and rubella vaccines. A report of the Committee to Review the Adverse Consequences of Pertussis and Rubella Vaccines. National Academy Press: Washington, DC, 1991.
- 184 Quast U, Thilo W, Fescharek R. Impfreaktionen – Bewertung und Differentialdiagnose. 2. Auflage. Hippokrates, Stuttgart 1997. Kapitel Röteln, S 112–118.
- 185 Plotkin SA. Rubella vaccines. In: Plotkin SA, Orenstein WA (eds) *Vaccines*. 3rd edition. Saunders, Philadelphia 1999, 409–440
- 186 Dittmann S. Rubella vaccine. In: *Meyler's Side Effect of Drugs* (eds. Dukes MNG, Aronson JK). Elsevier, Amsterdam 2000, pp 1092–1093.

Tetanus-Impfstoff

- 187 Quast U, Thilo W, Fescharek R. Impfreaktionen – Bewertung und Differentialdiagnose. 2. Auflage. Hippokrates, Stuttgart 1997. Kapitel Tetanus, S 119–124.
- 188 Dittmann S. Tetanus vaccine. In: *Meyler's Side Effect of Drugs* (eds. Dukes MNG, Aronson JK). Elsevier, Amsterdam 2000, pp 1094–1095.

Tetanus-Diphtherie-Pertussis (azellulär): Tdap-Impfstoff

- 189 Van der Wielen M, Van Damme P, Joossens E, François G, Meurice F, Ramalho A. A randomised controlled trial with a diphtheria-tetanus-acellular pertussis (dTpa) vaccine in adults. *Vaccine* 2000; 18: 2075–2082.

Tollwut-Impfstoff

- 190 Quast U, Thilo W, Fescharek R. Impfreaktionen – Bewertung und Differentialdiagnose. 2. Auflage. Hippokrates, Stuttgart 1997. Kapitel Tollwut, S 125–131.
- 191 Plotkin SA, Rupprecht CE. Rabies vaccine. In: Plotkin SA, Orenstein WA (eds) *Vaccines*. 3rd edition. Saunders, Philadelphia 1999, 743–766.
- 192 Supplementary information on vaccine safety – Background rates of adverse events following immunization. Section Adverse events following rabies vaccine. World Health Organization, Geneva 2000. WHO/V&B/00.36, pp 79–83.
- 193 Dittmann S. Rabies vaccine. In: *Meyler's Side Effect of Drugs* (eds. Dukes MNG, Aronson JK). Elsevier, Amsterdam 2000, pp 1090–1091
- 194 World Health Organization. Adverse events following rabies vaccine.
><http://www.who.int/vaccines-diseases/safety/infobank/rabies.shtml>< (Zugang: 3 Feb 2003)

Typhus-Oral-Impfstoff und Typhus-Polysaccharid-Impfstoff

- 195 Quast U, Thilo W, Fescharek R. Impfreaktionen – Bewertung und Differentialdiagnose. 2. Aufl. Hippokrates, Stuttgart 1997. Kapitel Typhus abdominalis, S 140–145.
- 196 Levine MM. Typhoid Fever vaccines. In: Plotkin SA, Orenstein WA (eds) Vaccines. 3rd edition. Saunders, Philadelphia 1999, 781–814.
- 197 Supplementary information on vaccine safety – Background rates of adverse events following immunization. Section Adverse events following typhoid vaccine. World Health Organization, Geneva 2000. WHO/V&B/00.36, pp 89–92.
- 198 Dittmann S. Typhoid vaccine. In: Meyler's Side Effect of Drugs (eds. Dukes MNG, Aronson JK). Elsevier, Amsterdam 2000, pp 1096.
- 199 World Health Organization. Adverse events following typhoid vaccine.
><http://www.who.int/vaccines-diseases/safety/infobank/typhoid.shtml> (Zugang: 3 Feb 2003)

Varizellen-Impfstoff

- 200 Quast U, Thilo W, Fescharek R. Impfreaktionen – Bewertung und Differentialdiagnose. 2. Auflage. Hippokrates, Stuttgart 1997. Kapitel Varizellen, Zoster. S 146–150.
- 201 Gershon AA, Takahashi M, White CJo. Varicella vaccine. In: Plotkin SA, Orenstein WA (eds). Vaccines. 3rd edition. Saunders, Philadelphia 1999, 475–507.
- 202 Wise RT, Salive ME, Braun M, Mootrey GT, Seward JF, Rider LG, Krause PR. Postlicensure safety for varicella vaccine. *J Amer Med Assoc* 2000; 284: 1271–1279
- 203 Dittmann S. Varicella vaccine. In: Meyler's Side Effect of Drugs (eds. Dukes MNG, Aronson JK). Elsevier, Amsterdam 2000, pp 1096–1097.
- 204 Supplementary information on vaccine safety – Background rates of adverse events following immunization. Section Adverse events following varicella vaccine. World Health Organization, Geneva 2000. WHO/V&B/00.3, pp 93–96.
- 205 Sharrar RG, La Russa P, Galea SA, Steinberg SP, Sweet AR, Keatley RM, Wells ME, Stephenson W, Gershon A. The postmarketing safety profile of varicella vaccine. *Vaccine* 2001; 19: 916–923.
- 206 World Health Organization. Adverse events following varicella vaccine.
><http://www.who.int/vaccines-diseases/safety/infobank/varicella.shtml> (Zugang: 3 Feb 2003)

Übersichtsliteratur

- 207 Howson CP, Howe CJ, Fineberg HV, eds. Adverse effects of pertussis and rubella vaccines. A report of the Committee to Review the Adverse Consequences of Pertussis and Rubella Vaccines. National Academy Press: Washington, DC, 1991.

- 208 Stratton KR, Howe CJ, Johnston RB Jr, eds. Adverse events associated with childhood vaccines. National Academy of Sciences: Washington, DC, 1994.
- 209 Recommendations of the Advisory Committee on Immunization Practices (ACIP). Update: Vaccine side effects, adverse reactions, contraindications, and precautions. *Morbidity and Mortality* 1996; 45: No RR-12.
- 210 Quast U, Thilo W, Fescharek R. Impfreaktionen – Bewertung und Differentialdiagnose. 2. Auflage. Hippokrates, Stuttgart 1997.
- 211 Plotkin SA, Orenstein WA (eds) Vaccines. 3rd edition. Saunders, Philadelphia 1999
- 212 Supplementary information on vaccine safety – Background rates of adverse events following immunization. World Health Organization, Geneva 2000. WHO/V&B/00.36
- 213 Dittmann S. Vaccines. In: Meyler's Side Effect of Drugs (eds. Dukes MNG, Aronson JK). Elsevier, Amsterdam 2000, pp 1047–1110.
- 214 American Academy of Pediatrics. Pickering LK, ed. 2000 Red Book: Report of the Committee on Infectious Diseases. 25th ed. Elk Grove Village, IL; American Academy of Pediatrics 2000.
- 215 Chen RT, Mootrey G, DeStefano F. Safety of routine childhood vaccinations: An epidemiological review. *Pediatr Drugs* 2000; 2: 273–290.
- 216 Dittmann S. Das Risiko des Impfens und das weit größere Risiko nicht geimpft zu sein. *Bundesgesundheitsblatt* 2002; 45: 316–320.
- 217 Jilg W, Dittmann S. Impfen (CD-ROM, 3. Auflage) Thieme, Stuttgart 2002.
- 218 Handbuch Infektionen bei Kindern und Jugendlichen. Herausgegeben von der Deutschen Gesellschaft für pädiatrische Infektiologie. Futuramed, München 2003.
- 219 Schutzimpfungen, 3. Auflage 2003 (Hrsg. Schmitt HJ, Hülse C, Raue W). Infomed Berlin 2003.

Übersichten zu Kinderimpfstoffen und Diabetes

- 220 Jefferson T. Vaccination and its adverse effects: Real or perceived *Br Med J*. 1998; 317: 159–160.
- 221 Childhood immunizations and type 1 diabetes. Summary of an Institute for Vaccine Safety workshop. *Pediatr Infect Dis J* 1999; 18: 217–222.
- 222 DeStefano F, Mullooly J, Okoro CA, Chen RT, Marcy M, Ward JI, Vadheim C, Black SB, Shinefield H, Davis RL, Bohlke K, and the Vaccine Safety Datalink Team: Childhood vaccinations, vaccination timing, and risk of type 1 diabetes mellitus. *Pediatrics* 2002; 108: e112.
- 223 World Health Organization. Diabetes.
><http://www.who.int/vaccines-diseases/safety/infobank/diabetes.shtml> (Zugang: 3 Feb 2003)
- 224 Keller-Stanislawski B, Hartmann K. Existiert ein Zusammenhang zwischen Impfungen und Typ 1-Diabetes mellitus und Impfungen bei Kindern und Jugendlichen. *Bundesgesundheitsbl – Gesundheitsforsch – Gesundheitsschutz* 2001; 44: 613–618.

Hinweis zur angegebenen Literatur

Die ausführliche Literaturliste zum Beitrag „Hinweise für Ärzte zum Aufklärungsbedarf bei Schutzimpfungen/Stand: Januar 2004“ findet sich auf den Internetseiten des RKI zum Impfen unter <http://www.rki.de/GESUND/IMPFFEN/IMPFFEN.HTM>.

Bezugsmöglichkeiten der „Hinweise für Ärzte zum Aufklärungsbedarf bei Schutzimpfungen/Stand: Januar 2004“ der Ständigen Impfkommission (STIKO) am RKI

Einzel Exemplare können beim RKI zu folgenden Bedingungen angefordert werden:

- ▶ **kostenfrei bis zu 5 Exemplare nach Einsenden der Adresse und Briefmarken im Wert von 1,44 €** (kein Rückumschlag!),
- ▶ **6–20 Exemplare** gegen Rechnung zum Stückpreis von **0,60 €**,
- ▶ **21–50 Exemplare** gegen Rechnung zum Stückpreis von **0,50 €**,
- ▶ **mehr als 50 Exemplare** gegen Rechnung zum Stückpreis von **0,45 €**.

Bei der Aussendung können Wartezeiten eintreten.

Wir bitten, zur Bestellung die folgende Adresse zu verwenden und von telefonischen Bestellungen Abstand zu nehmen:

Robert Koch-Institut
Stichwort „Aufklärungen zu Impfungen“
Nordufer 20
13353 Berlin

Bestellungen von **mehr als 5 Exemplaren gegen Rechnung** können auch an folgende Adressen gerichtet werden:

- ▶ Fax: 01888.754-2459
- ▶ E-Mail: EpiBull@rki.de

Die „Hinweise für Ärzte zum Aufklärungsbedarf bei Schutzimpfungen / Stand: Januar 2004“ der Ständigen Impfkommission (STIKO) am RKI sind auch im Internet abrufbar unter:
<http://www.rki.de/GESUND/IMPFFEN/IMPFFEN.HTM>.

Bei Verbreitung dieser Ankündigung wird gebeten, die Bezugsbedingungen korrekt wiederzugeben. Falls ein Nachdruck in anderen Zeitschriften gewünscht ist, wird gebeten, die Redaktion des *Epidemiologischen Bulletins* zu kontaktieren.

Impressum

Herausgeber

Robert Koch-Institut
 Nordufer 20, 13353 Berlin

Tel.: 01888.754-0
 Fax: 01888.754-2628
 E-Mail: EpiBull@rki.de

Redaktion

Dr. med. Ines Steffens, MPH (v. i. S. d. P.)
 Tel.: 01888.754-2324
 E-Mail: SteffensI@rki.de

Sylvia Fehrmann
 Tel.: 01888.754-2455
 E-Mail: FehrmannS@rki.de

Fax.: 01888.754-2459

Vertrieb und Abonentenservice

Plusprint Versand Service
 Thomas Schönhoff
 Bucher Weg 18, 16321 Lindenberg
 Abo-Tel.: 030.948781-3

Das Epidemiologische Bulletin

gewährleistet im Rahmen des infektions-epidemiologischen Netzwerks einen raschen Informationsaustausch zwischen den verschiedenen Akteuren – den Ärzten in Praxen, Kliniken, Laboratorien, Beratungsstellen und Einrichtungen des öffentlichen Gesundheitsdienstes sowie den medizinischen Fachgesellschaften, Nationalen Referenzzentren und den Stätten der Forschung und Lehre – und dient damit der Optimierung der Prävention.

Herausgeber und Redaktion erbitten eine aktive Unterstützung durch die Übermittlung allgemein interessierender Mitteilungen, Analysen und Fallberichte. Das Einverständnis mit einer redaktionellen Überarbeitung wird dabei vorausgesetzt.

Das *Epidemiologische Bulletin* erscheint in der Regel wöchentlich (50 Ausgaben pro Jahr). Es kann im Jahresabonnement für einen Unkostenbeitrag von € 49,- per Beginn des Kalenderjahres bezogen werden; bei Bestellung nach Jahresbeginn errechnet sich der Beitrag mit € 4,- je Bezugsmonat. Ohne Kündigung bis Ende November verlängert sich das Abonnement um ein Jahr.

Die **aktuelle** Ausgabe des *Epidemiologischen Bulletins* kann über die **Fax-Abruffunktion** (Polling) unter 01888.754-2265 abgerufen werden. – Die Ausgaben ab 1997 stehen im **Internet** zur Verfügung unter:
<http://www.rki.de/INFEKT/EPIBULL/EPI.HTM>.

Druck

die partner, karl-heinz kronauer, berlin

Nachdruck

mit Quellenangabe gestattet, jedoch nicht zu werblichen Zwecken. Belegexemplar erbeten. Die Weitergabe in elektronischer Form bedarf der Zustimmung der Redaktion.

ISSN 1430-0265 (Druck)

ISSN 1430-1172 (Fax)

PVKZ A 14273